Where to find us

About UCB Ventures

UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further
strengthen UCB's ability to create value from novel insights and technologies that can transform the
lives of patients suffering from severe diseases.

We invest in innovative therapeutics and technology platforms that are early stage and higher risk,
in areas adjacent to or even beyond UCB's therapeutic focus on neurology/neurodegenerative diseases,
immunology and muscular skeletal/bone health.

Our team initially made four fund-to-fund investments in selected Healthcare Venture Funds in 2017,
and is now focused on long term, direct investments in the US and Europe. Our first direct investment is
in StrideBio, a US-based gene therapy company, with several more investments to come in the near future.

News

UCB Ventures makes its first direct investment

Brussels, Belgium, 13 June 2018. —
Today, UCB Ventures announces its first direct investment in the oversubscribed $15.7 million Series
A Financing Round for StrideBio, Inc., a US-based biotechnology company developing novel adeno-associated
viral (AAV) vectors for in vivo gene therapies of rare diseases. The financing was led by Hatteras
Venture Partners, and in addition to UCB Ventures, co-investors include Takeda Ventures, Inc. and
Alexandria Venture Investments, LLC. Erica Whittaker, PhD, Vice President, Head of UCB Ventures, and
Jayson Punwani, PhD, Partner, Takeda Ventures, Inc. have joined StrideBio's Board of Directors.